Company News

The US-based Hamilton team has developed a novel Cas9-EDV delivery system, achieving precise in vivo editing of human T cells for the first time and paving a safe and efficient new path for gene therapy.

The 2025 Nobel Prize in Physiology or Medicine has been awarded to three immunologists for their pioneering discoveries concerning the mechanism of peripheral immune tolerance. The laureates are Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi.

Phage Display Technology: Market Prospect Analysis And Research Progress

Literature Title: Dual CD47 and PD-L1 blockade elicits anti-tumor immunity by intratumoral CD8+ T cells.

On July 31, 2024, in the journal Scientific Reports, Nam Ju Lee et al. published a paper titled A single domain antibody library based on a stability-engineered human VH3 scaffold.

On December 23, 2024, Fan Bu et al. published a paper titled "Discovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection" in the journal PLOS Pathogens.

On September 12, 2024, Carli M. Stewart and colleagues published a pivotal article in Nature Communications, highlighting the role of Interleukin-4 (IL-in driving the exhaustion of CD8+ CAR T cells, a critical aspect of CAR T cell therapy. This breakthrough could have significant ramifications for companies like Alpha Lifetech Incorporation, which are actively engaged in advancing immunotherapy techniques.

A recent study published in Nature Communications on August 13, 2023, reveals that the complementarity determining region (CDR) loop in a single chain variable fragment (scFv) can induce CAR aggregation, leading to significant issues in chimeric antigen receptor (CAR)-T cell therapy. The implications of this research highlight critical challenges in enhancing the efficacy of CAR-T cell therapies, a focus of ongoing investigation in the field, particularly for companies like Alpha Lifetech Incorporation, which is dedicated to advancing CAR technology.

On June 1, 2024, in the journal Nature Communications, scientists from Bo Li's research team published an article titled "Area postrema neurons mediate interleukin-6 function in cancer cachexia". The article found that sustained elevation of interleukin-6 can lead to brain dysfunction and ultimately cancer cachexia.

On July 11, 2024, a team of researchers led by Dr. Judith Sebolt Leopold designed a kinase inhibitor MTX-531 that can block epidermal growth factor receptor (EGFR) and phosphatidylinositol 3-OH kinase (PI3K).